Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) traded down 3.8% during trading on Friday . The company traded as low as $13.10 and last traded at $13.49. 1,470,132 shares changed hands during mid-day trading, an increase of 335% from the average session volume of 337,931 shares. The stock had previously closed at $14.02.
Silverback Therapeutics Stock Performance
The stock has a market capitalization of $436.30 million, a PE ratio of -5.00 and a beta of 0.60. The stock's 50-day moving average is $13.26 and its 200 day moving average is $12.89.
About Silverback Therapeutics
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
